67245-85-6

Usage

Uses

Used in Organic Synthesis:
MALONIC ACID BIS(4-NITROBENZYL) ESTER is used as a reagent for introducing the malonate ester functionality in molecules, which is essential for the synthesis of various organic compounds.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, MALONIC ACID BIS(4-NITROBENZYL) ESTER is used as a starting material for the synthesis of biologically active compounds, contributing to the development of new drugs and therapeutic agents.
Used in Fine Chemicals Preparation:
MALONIC ACID BIS(4-NITROBENZYL) ESTER is employed in the preparation of fine chemicals, where its malonate ester functionality is incorporated into the molecular structures of these specialty chemicals.
Used in Complex Organic Molecules Synthesis:
As a building block, MALONIC ACID BIS(4-NITROBENZYL) ESTER is used in the synthesis of complex organic molecules, facilitating the creation of intricate chemical structures for various applications.

InChI:InChI=1/C17H14N2O8/c20-16(26-10-12-1-5-14(6-2-12)18(22)23)9-17(21)27-11-13-3-7-15(8-4-13)19(24)25/h1-8H,9-11H2

Upstream product

• 141-82-2 malonic acid 
• 100-11-8 1-bromomethyl-4-nitro-benzene 

Downstream Products

• 65750-58-5 bis(p-nitrobenzyl) ketomalonate 
• 82551-61-9 di-p-nitrobenzyl α-diazomalonate 
• 113897-67-9 (3R,4R)-3-(N-carbomethoxy-N-methyl)amino-4-[3-(p-nitrobenzyloxycarbonyl)-2-oxopropyl]-2-azetidinone 
• 77359-11-6 propanedioic acid mono[(4-nitrophenyl)methyl] ester 
• 65750-60-9 2-Chloro-2-{(2S,3S)-2-{(E)-2-[2-(4-nitro-benzyloxycarbonylamino)-ethylsulfanyl]-vinyl}-3-[(S)-1-(4-nitro-benzyloxycarbonyloxy)-ethyl]-4-oxo-azetidin-1-yl}-malonic acid bis-(4-nitro-benzyl) ester 
• 65794-50-5 2-Chloro-2-{(2S,3S)-2-{(E)-2-[2-(4-nitro-benzyloxycarbonylamino)-ethylsulfanyl]-vinyl}-3-[1-(4-nitro-benzyloxycarbonyloxy)-ethyl]-4-oxo-azetidin-1-yl}-malonic acid bis-(4-nitro-benzyl) ester 
• 65750-61-0 2-Hydroxy-2-{(2S,3S)-2-{(E)-2-[2-(4-nitro-benzyloxycarbonylamino)-ethylsulfanyl]-vinyl}-3-[(S)-1-(4-nitro-benzyloxycarbonyloxy)-ethyl]-4-oxo-azetidin-1-yl}-malonic acid bis-(4-nitro-benzyl) ester 
• 65750-61-0 2-Hydroxy-2-{(2S,3S)-2-{(Z)-2-[2-(4-nitro-benzyloxycarbonylamino)-ethylsulfanyl]-vinyl}-3-[(S)-1-(4-nitro-benzyloxycarbonyloxy)-ethyl]-4-oxo-azetidin-1-yl}-malonic acid bis-(4-nitro-benzyl) ester 
• 65750-61-0 2-Hydroxy-2-{(2S,3S)-2-{(E)-2-[2-(4-nitro-benzyloxycarbonylamino)-ethylsulfanyl]-vinyl}-3-[1-(4-nitro-benzyloxycarbonyloxy)-ethyl]-4-oxo-azetidin-1-yl}-malonic acid bis-(4-nitro-benzyl) ester 
• 72843-07-3 2-Hydroxy-2-{(2S,3S)-2-{(Z)-2-[2-(4-nitro-benzyloxycarbonylamino)-ethylsulfanyl]-vinyl}-3-[1-(4-nitro-benzyloxycarbonyloxy)-ethyl]-4-oxo-azetidin-1-yl}-malonic acid bis-(4-nitro-benzyl) ester 
• 65750-53-0 2-{(2S,3S)-2-{(E)-2-[2-(4-Nitro-benzyloxycarbonylamino)-ethylsulfanyl]-vinyl}-3-[(S)-1-(4-nitro-benzyloxycarbonyloxy)-ethyl]-4-oxo-azetidin-1-yl}-malonic acid bis-(4-nitro-benzyl) ester 
• 65794-49-2 2-{(2S,3S)-2-{(E)-2-[2-(4-Nitro-benzyloxycarbonylamino)-ethylsulfanyl]-vinyl}-3-[1-(4-nitro-benzyloxycarbonyloxy)-ethyl]-4-oxo-azetidin-1-yl}-malonic acid bis-(4-nitro-benzyl) ester 
• 65750-54-1 (4S,5R,6R)-4-Bromo-3-[2-(4-nitro-benzyloxycarbonylamino)-ethylsulfanyl]-6-[(R)-1-(4-nitro-benzyloxycarbonyloxy)-ethyl]-7-oxo-1-aza-bicyclo[3.2.0]heptane-2,2-dicarboxylic acid bis-(4-nitro-benzyl) ester 
• 65750-54-1 (4S,5R,6R)-4-Bromo-3-[2-(4-nitro-benzyloxycarbonylamino)-ethylsulfanyl]-6-[1-(4-nitro-benzyloxycarbonyloxy)-ethyl]-7-oxo-1-aza-bicyclo[3.2.0]heptane-2,2-dicarboxylic acid bis-(4-nitro-benzyl) ester 

Relevant academic research and scientific papers

3-Substituted-6-(1'-hydroxyethyl)-7-oxo-1-azabicyclo[3.2.0]-hept-2-ene-2-carboxylic acid

Disclosed are 3-substituted-6-(1'-hydroxyethyl)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acids having the structure: STR1 wherein R8 is, inter alia, selected from the group consisting of hydrogen, alkyl, alkenyl, aryl and aralkyl. Such

2-, 5-, and 6-Substituted-1-carbadethiapen-2-em-3-carboxylic acids

Disclosed are 2-, 5- and 6-substituted-1-carbadethiapen-2-em-3-carboxylic acids having the structure: STR1 wherein R6, R7, R8 and R9 are, inter alia, independently selected from the group consisting of hydrogen,

3-(2-Aminoethylthio)-6-amido-7-oxo-1-azabicyclo[3.2.0]-hept-2-ene-2-carboxylic acid

Disclosed are 3-(2-aminoethylthio)-6-amido-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acids having the structure: STR1 wherein R1 is hydrogen or acyl. Such compounds as well as their pharmaceutically acceptable salt, ester and amide derivatives are useful as antibiotics. Also disclosed are processes for the preparation of such compounds, pharmaceutical compositions comprising such compounds and methods of treatment comprising administering such compounds and compositions when an antibiotic effect is indicated.

3-Substituted thio-6-amido-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

Disclosed are 3-substituted thio-6-amido-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acids having the structure: STR1 wherein: R1 is hydrogen or acyl and R8 is, inter alia, independently selected from the group consisting of hydrogen, alkyl, alkenyl, aryl and aralkyl. Such compounds as well as their pharmaceutically acceptable salt, ester and amide derivatives are useful as antibiotics. Also disclosed are processes for the preparation of such compounds, pharmaceutical compositions comprising such compounds and methods of treatment comprising administering such compounds and compositions when an antibiotic effect is indicated.

3-(2-Aminoethylthio)-6-(1-hydroxyethyl)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

Isomeric forms of 3-(2-aminoethylthio)-6-(1-hydroxyethyl)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid (I) STR1 are disclosed; also disclosed is a process for their total synthesis; such isomers individually, and as mixtures, are useful as antibiotics.

Thienamycin Total Synthesis. 3. Total Synthesis of (+/-)-Thienamycin and (+/-)-8-Epithienamycin

The completion of the total synthesis of (+/-)-8-epithienamycin and (+/-)-thienamycin from azetidinones 3a and 3b using the methodology developed for the synthesis of model compound 4 (see part 2) is described.